Right Decisions
TAM (Treatments and Medicines) NHS Highland
FORMULARIES
HIGHLAND FORMULARY
CARDIOVASCULAR SYSTEM
Back
Hypertension and heart failure
Transthyretin amyloid cardiomyopathy (ATTR-CM) (Formulary)

Update your RDS mobile app to v4.7.2 to download toolkits even when website is down.

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. You will see that each toolkit has a small QR code icon in the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively update to the latest release - RDS app version 4.7.1 - to see this improvement.

Updating to this latest version of the RDS app is also strongly recommended to get the full benefits of the new resilience arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Transthyretin amyloid cardiomyopathy (ATTR-CM) (Formulary)

TAM (Treatments and Medicines) NHS Highland

What's new / Latest updates

29/02/24 - Tafamidis capsules 61mg SMC2585 added.

TAFAMIDIS

Important: Therapy notes

Risk minimisation materials

Exclude pregnancy before treatment and ensure effective contraception during and for one month after stopping treatment.

Important: Formulation and dosage details

Formulation:

Capsules 61mg (Restricted: Specialist use only)

Dosage:

SMC2585: for the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Patients will be initiated on treatment by cardiology.
Patients will be reviewed 6-monthly in the cardiology clinic throughout treatment.
Decision to stop can be made in primary care, eg if the patient’s clinical condition has changed and the patient is considered to have end-stage illness or unacceptable drug intolerance. Cardiology should be informed via Clinical Dialogue.